Alzheimer Research Initiative Reports Improvement in Drug Availability

The Alzheimer Research Initiative (AFI) has announced that the persistent supply issues for galantamine, a key medication used in Alzheimer's disease treatment, are beginning to ease. While availability is not yet fully normalized, the situation has seen some improvement recently. The scarcity of galantamine has been a concern for patients and their caregivers for an extended period.

In related news, AFI confirmed that Kisunla (donanemab) became available in Germany on November 4, 2025. This new treatment option represents a significant advancement in managing Alzheimer's disease symptoms, offering a new therapeutic avenue for patients in the German market.

The initiative has also expanded its educational resources with the release of two new brochures. The first, "Being There for People with Dementia," aims to support family caregivers by addressing the challenges of daily care and disease progression. The second, "Understanding Vascular Dementia," provides orientation on the second most common form of dementia in Germany, affecting approximately 250,000 individuals.

AFI continues its commitment to funding research, recently raising €37,868 for Alzheimer's research through the "Loot für die Welt" campaign. The organization focuses on advancing brain health and providing accessible information and support to all stakeholders.